09/03/2026
š Calling all osteosarcoma researchers! Donāt forget to submit your Letter of Intent for OSI grant funding. Deadline is Thursday, September 10, at 12:00 p.m. ET.
Since 2017, OSI has committed nearly $12 million in funding to advance breakthrough osteosarcoma clinical trials and science. This is all in an effort to increase osteosarcoma treatment options and survival rates.
If youāre working on promising, breakthrough osteosarcoma research, we want to hear from you.
OSI offers grants for clinical trials, correlative science, preclinical/translational, and high-risk/high-impact programs that move osteosarcoma research forward.
⢠Applicants must hold an MD, PhD, or equivalent, with a faculty appointment at an academic institution. You need not be a U.S. citizen.
⢠Funds must be granted to nonprofit/charitable institutions or organizations. They may be based in the U.S. or abroad.
⢠Applicants must have a track record of publication and funding productivity that demonstrates the project can be accomplished by the investigators.
⢠Selected applicants will be invited to submit a full proposal in early 2027.
⢠Funding decisions will be announced in June 2027.
Learn more about the eligibility criteria and submit your LOI today.
osinst.org/researchers/